FDA has yet to confirm Yutrepia for pulmonary hypertension-ILD

The FDA did not meet its Prescription Drug User Fee Act goal date that would extend Yutrepia as a treatment for patients with pulmonary hypertension associated with interstitial lung disease, according to a press release.
As noted in the release, Yutrepia (treprostinil, Liquidia Corporation) — an investigational, inhaled dry powder formulation of treprostinil — was tentatively approved for patients with pulmonary arterial hypertension (PAH) New York Heart Association functional class II and class III symptoms in November 2021.
Liquidia requested the addition of pulmonary

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart